Emerging moulds: Epidemiological trends and antifungal resistance

Mycoses

Volumn 54, Issue 6, 2011, Pages

  Miceli, Marisa H ^a   Lee, Samuel A ^b,c  

^a OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

Antifungal resistance; Epidemiology; Invasive mould infection

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ACREMONIUM; ALTERNARIA; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; ASPERGILLUS USTUS; BLOOD CULTURE; BREAST ENDOPROSTHESIS; CONTACT LENS; CURVULARIA; EPIDEMIC; EXOPHIALA; FUNGUS TRANSMISSION; FUSARIOSIS; FUSARIUM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; KERATITIS; MORBIDITY; MORTALITY; MUCOR; MUCORALES; MUCORMYCOSIS; MYCOSIS; NONHUMAN; PAECILOMYCES; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHIZOPUS; SPOROTRICHOSIS; TRICHOPHYTON VERRUCOSUM; WATER CONTAMINATION;

ANTIFUNGAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MYCOSES;

ASPERGILLUS; FUNGI; FUSARIUM; MUCORALES;

EID: 80053981736     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02032.x     Document Type: Review

References (140)

1. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16: 875-94, vi.
2. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-6.
3. Kobayashi K, Kami M, Murashige N, Kishi Y, Fujisaki G, Mitamura T. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica 2004; 89: ECR42.
4. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-2.
5. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584-7.
6. Glasmacher A, Hahn C, Marklein G, Djulbegovic B, Prentice A. Incidence of Breakthrough Invasive Fungal Infections with Non-albicans Candida Species and Zygomycetes After Phrophylaxis with Itraconazole: Data From a Meta-analysis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, D.C. 2005, p. M-993.
7. Park BJ, Pappas PG, Marr KA et al. Recent Epidemiology of Zygomycosis among Organ Transplant and Stem Cell Transplant Recipients; Results from the TRANSNET Surveillance Network. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL, 2007, p. M-618.
8. Procop GW, Roberts GD. Emerging fungal diseases: the importance of the host. Clin Lab Med 2004; 24: 691-719. vi-vii.
9. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
10. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-60.
11. Hagen EA, Stern H, Porter D et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36: 9-15.
12. Pappas PG, Kauffman C, Alexander B et al. Prospective Surveillance of Invasive Fungal Infections (IFIs) among Organ Transplant Recipients (OTRs) in the U.S. 2001-2006: review of TRANSNET. 47th Interscience COnference on Antimicrobial Agents and Chemotherapy; September 17-23, 2007; Chicago, IL, 2007, p. M-1195.
13. Horn DL, Fishman JA, Steinbach WJ et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007; 59: 407-14.
14. Fluckiger U, Marchetti O, Bille J et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006; 136: 447-63.
15. Spanish Network of Infection in Transplantation (RESITRA). RESITRA Network. (last accessed on 21 March 2011).
16. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
17. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005; 40: 770-1.
18. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-42.
19. Balajee SA, Kano R, Baddley JW et al. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3138-41.
20. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 2005; 4: 625-32.
21. Weiss LM, Thiemke WA. Disseminated Aspergillus ustus infection following cardiac surgery. Am J Clin Pathol 1983; 80: 408-11.
22. Vagefi PA, Cosimi AB, Ginns LC, Kotton CN. Cutaneous Aspergillus ustus in a lung transplant recipient: emergence of a new opportunistic fungal pathogen. J Heart Lung Transplant 2008; 27: 131-4.
23. Pavie J, Lacroix C, Hermoso DG et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005; 43: 4902-4.
24. Verweij PE, van den Bergh MF, Rath PM, de Pauw BE, Voss A, Meis JF. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol 1999; 37: 1606-9.
25. Iwen PC, Rupp ME, Bishop MR et al. Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation. J Clin Microbiol 1998; 36: 3713-7.
26. Yildiran ST, Mutlu FM, Saracli MA et al. Fungal endophthalmitis caused by Aspergillus ustus in a patient following cataract surgery. Med Mycol 2006; 44: 665-9.
27. Nakai K, Kanda Y, Mineishi S et al. Primary cutaneous aspergillosis caused by Aspergillus ustus following reduced-intensity stem cell transplantation. Ann Hematol 2002; 81: 593-6.
28. Gene J, Azon-Masoliver A, Guarro J et al. Cutaneous infection caused by Aspergillus ustus, an emerging opportunistic fungus in immunosuppressed patients. J Clin Microbiol 2001; 39: 1134-6.
29. Stiller MJ, Teperman L, Rosenthal SA et al. Primary cutaneous infection by Aspergillus ustus in a 62-year-old liver transplant recipient. J Am Acad Dermatol 1994; 31(2 Pt 2): 344-7.
30. Ricci RM, Evans JS, Meffert JJ, Kaufman L, Sadkowski LC. Primary cutaneous Aspergillus ustus infection: second reported case. J Am Acad Dermatol 1998; 38(5 Pt 2): 797-8.
31. Saracli MA, Mutlu FM, Yildiran ST et al. Clustering of invasive Aspergillus ustus eye infections in a tertiary care hospital: a molecular epidemiologic study of an uncommon species. Med Mycol 2007; 45: 377-84.
32. Panackal AA, Imhof A, Hanley EW, Marr KA. Aspergillus ustus infections among transplant recipients. Emerg Infect Dis 2006; 12: 403-8.
33. Varga J, Houbraken J, Van Der Lee HA, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell 2008; 7: 630-8.
34. Hageskal G, Kristensen R, Fristad RF, Skaar I. Emerging pathogen Aspergillus calidoustus colonizes water distribution systems. Med Mycol 2011; 1-6 [Epub ahead of print].
35. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis 2006; 43: 1580-4.
36. Steinbach WJ, Perfect JR. Scedosporium species infections and treatments. J Chemother 2003; 15(Suppl. 2): 16-27.
37. Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 1983; 36: 259-67.
38. Wajszczuk CP, Dummer JS, Ho M et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347-53.
39. Singh N, Aguado J, Bonatti H et al. Risk Factors for Zygomycosis In Solid Organ Transplant Recipients: A Prospective, Case-Controlled, Multicenter, International Study 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL, 2007, p. M-1192.
40. Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001; 32: 1237-40.
41. Husain S, Munoz P, Forrest G et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
42. Castiglioni B, Sutton DA, Rinaldi MG, Fung J, Kusne S. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 2002; 81: 333-48.
43. Imhof A, Schaer DJ, Schoedon G, Kurrer MO, Schneemann M. 10 Year Postmortem Analysis of Filamentous Fungal Infections in a Tertiary Care Hospital. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007; Chicago, IL, 2007, p. M-623.
44. Ruiz N, Fernandez-Martos C, Romero I et al. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol 2007; 25: 3376-7.
45. Singh P, Taylor SF, Murali R, Gomes LJ, Kanthan GL, Maloof AJ. Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor. Clin Experiment Ophthalmol 2007; 35: 275-80.
46. Latenser BA. Fusarium infections in burn patients: a case report and review of the literature. J Burn Care Rehabil 2003; 24: 285-8.
47. Sierra-Hoffman M, Paltiyevich-Gibson S, Carpenter JL, Hurley DL. Fusarium osteomyelitis: case report and review of the literature. Scand J Infect Dis 2005; 37: 237-40.
48. Merchant S, Reichman R, Koval CE. Rhinocerebral zygomycosis in an HIV-infected man during therapy with an investigational CCR5 inhibitor. AIDS 2007; 21: 1666-9.
49. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006; 55(Pt 7): 809-18.
50. Mansoory D, Roozbahany NA, Mazinany H, Samimagam A. Chronic Fusarium infection in an adult patient with undiagnosed chronic granulomatous disease. Clin Infect Dis 2003; 37: e107-8.
51. Cortez KJ, Roilides E, Quiroz-Telles F et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21: 157-97.
52. Perdomo H, Sutton DA, Garcia D et al. Spectrum of clinically relevant Acremonium species in the United States. J Clin Microbiol 2011; 49: 243-56.
53. Miyakis S, Velegraki A, Delikou S et al. Invasive Acremonium strictum infection in a bone marrow transplant recipient. Pediatr Infect Dis J 2006; 25: 273-5.
54. Das S, Saha R, Dar SA, Ramachandran VG. Acremonium species: a review of the etiological agents of emerging hyalohyphomycosis. Mycopathologia 2010; 170: 361-75.
55. Yamazaki R, Mori T, Aisa Y et al. Systemic infection due to Acremonium after allogeneic peripheral blood stem cell transplantation. Intern Med 2006; 45: 989-90.
56. Keynan Y, Sprecher H, Weber G. Acremonium vertebral osteomyelitis: molecular diagnosis and response to voriconazole. Clin Infect Dis 2007; 45: e5-e6.
57. Koc AN, Mutlu Sariguzel F, Artis T. Pleuritis caused by Acremonium strictum in a patient with colon adenocarcinoma. Mycoses 2008; 51: 554-6.
58. Joe SG, Lim J, Lee JY, Yoon YH. Case report of Acremonium intraocular infection after cataract extraction. Korean J Ophthalmol 2010; 24: 119-22.
59. Koc AN, Utas C, Oymak O, Sehmen E. Peritonitis due to Acremonium strictum in a patient on continuous ambulatory peritoneal dialysis. Nephron 1998; 79: 357-8.
60. Purnak T, Beyazit Y, Sahin GO, Shorbagi A, Akova M. A novel fungal pathogen under the spotlight -Acremonium spp. associated fungaemia in an immunocompetent host. Mycoses 2011; 54: 78-80.
61. Geyer AS, Fox LP, Husain S, Della-Latta P, Grossman ME. Acremonium mycetoma in a heart transplant recipient. J Am Acad Dermatol 2006; 55: 1095-100.
62. Tuon FF, Pozzi C, Penteado-Filho SR, Benvenutti R, Contieri FL. Recurrent Acremonium infection in a kidney transplant patient treated with voriconazole: a case report. Rev Soc Bras Med Trop 2010; 43: 467-8.
63. Durbec M, Bienvenu AL, Picot S, Dubreuil C, Cosmidis A, Tringali S. Maxillary sinus fungal infection by Acremonium. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128: 41-3.
64. Chang DC, Grant GB, O'Donnell K et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006; 296: 953-63.
65. Anaissie EJ, Kuchar RT, Rex JH et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33: 1871-8.
66. Nucci M, Godoy P, Seber A, Petrilli As, Colombo AL. An Outbreak of Invasive Fusariosis Associated with Contamination of the Hospital Water System. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA, 2006, p. M-881.
67. Dignani MC, Perrotta D, Abrantes R et al. Molds in Hospital Air: Data From a Single Oncohematological Institution in Argentina. 14th International Symposium on Infections in the Immunocompromised Host July 2-5, 2006; Crans-Montana, Switzerland, 2006, p. 128.
68. Nucci M, Akiti T, Barreiros G et al. Nosocomial outbreak of Exophiala jeanselmei fungemia associated with contamination of hospital water. Clin Infect Dis 2002; 34: 1475-80.
69. Truppman ES, Ellenby JD, Schwartz BM. Fungi in and around implants after augmentation mammaplasty. Plast Reconstr Surg 1979; 64: 804-6.
70. Williams K, Walton RL, Bunkis J. Aspergillus colonization associated with bilateral silicone mammary implants. Plast Reconstr Surg 1983; 71: 260-1.
71. Young VL, Hertl MC, Murray PR, Lambros VS. Paecilomyces variotii contamination in the lumen of a saline-filled breast implant. Plast Reconstr Surg 1995; 96: 1430-4.
72. Kainer MA, Keshavarz H, Jensen BJ et al. Saline-filled breast implant contamination with Curvularia species among women who underwent cosmetic breast augmentation. J Infect Dis 2005; 192: 170-7.
73. Chan TH, Koehler A, Li PK. Paecilomyces varioti peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 27: 138-42.
74. Hirst LW, Sebban A, Whitby RM, Nimmo GR, Stallard K. Non-traumatic mycotic keratitis. Eye 1992; 6(Pt 4): 391-5.
75. Mizunoya S, Watanabe Y. Paecilomyces keratitis with corneal perforation salvaged by a conjunctival flap and delayed keratoplasty. Br J Ophthalmol 1994; 78: 157-8.
76. Pettit TH, Olson RJ, Foos RY, Martin WJ. Fungal endophthalmitis following intraocular lens implantation. A surgical epidemic. Arch Ophthalmol 1980; 98: 1025-39.
77. Itin PH, Frei R, Lautenschlager S et al. Cutaneous manifestations of Paecilomyces lilacinus infection induced by a contaminated skin lotion in patients who are severely immunosuppressed. J Am Acad Dermatol 1998; 39: 401-9.
78. Strahilevitz J, Rahav G, Schroers HJ et al. An outbreak of Phialemonium infective endocarditis linked to intracavernous penile injections for the treatment of impotence. Clin Infect Dis 2005; 40: 781-6.
79. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy - United States, July-November 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 1109-12.
80. Schubach A, Schubach TM, Barros MB, Wanke B. Cat-transmitted sporotrichosis, Rio de Janeiro, Brazil. Emerg Infect Dis 2005; 11: 1952-4.
81. Schubach AO, Schubach TM, Barros MB. Epidemic cat-transmitted sporotrichosis. N Engl J Med 2005; 353: 1185-6.
82. Ming PX, Ti YL, Bulmer GS. Outbreak of Trichophyton verrucosum in China transmitted from cows to humans. Mycopathologia 2006; 161: 225-8.
83. Maslen MM. Human cases of cattle ringworm due to Trichophyton verrucosum in Victoria, Australia. Australas J Dermatol 2000; 41: 90-94.
84. Roman C, Massai L, Gianni C, Crosti C. Case reports. Six cases of infection due to Trichophyton verrucosum. Mycoses 2001; 44: 334-7.
85. Wabacha JK, Gitau GK, Bebora LC, Bwanga CO, Wamuri ZM, Mbithi PM. Occurrence of dermatomycosis (ringworm) due to Trichophyton verrucosum in dairy calves and its spread to animal attendants. J S Afr Vet Assoc 1998; 69: 172-3.
86. LeMaile-Williams M, Burwell LA, Salisbury D et al. Outbreak of cutaneous Rhizopus arrhizus infection associated with karaya ostomy bags. Clin Infect Dis 2006; 43: e83-e88.
87. Lass-Florl C, Rath P, Niederwieser D et al. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect 2000; 46: 31-35.
88. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000; 31: 188-9.
89. Lionakis MS, Bodey GP, Tarrand JJ, Raad II, Kontoyiannis DP. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients. Clin Microbiol Infect 2004; 10: 922-5.
90. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20: 711-27, viii.
91. Lee SA, Wong B. Advances in diagnostic methods for invasive Candida and Aspergillus infections. In: Domer J, Kobayashi GS (eds), The Mycota: A Comprehensive Treatise on Fungi as Experimental Systems for Basic and Applied Research. Berlin: Springer, 2004: 37-64.
92. Stynen D, Goris A, Sarfati J, Latge JP. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497-500.
93. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-9.
94. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-27.
95. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917-20.
96. Viscoli C, Machetti M, Cappellano P et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-6.
97. Swanink CM, Meis JF, Rijs AJ, Donnelly JP, Verweij PE. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997; 35: 257-60.
98. Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517-22.
99. Iwanaga S, Miyata T, Tokunaga F, Muta T. Molecular mechanism of hemolymph clotting system in Limulus. Thromb Res 1992; 68: 1-32.
100. Miyazaki T, Kohno S, Mitsutake K et al. Plasma (1→3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33: 3115-8.
101. Yoshida M, Obayashi T, Iwama A et al. Detection of plasma (1→3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997; 35: 371-4.
102. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky-Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006; 44: 267-72.
103. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
104. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003; 10: 882-5.
105. Ahmad S, Khan ZU, Theyyathel AM. Diagnostic value of DNA, (1-3)-beta-D-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with Aspergillus terreus. Diagn Microbiol Infect Dis 2007; 59: 165-71.
106. Mokaddas E, Burhamah MH, Ahmad S, Khan ZU. Invasive pulmonary aspergillosis due to Aspergillus terreus: value of DNA, galactomannan and (1→3)-beta-D-glucan detection in serum samples as an adjunct to diagnosis. J Med Microbiol 2010; 59(Pt 12): 1519-23.
107. del Palacio A, Alhambra A, Cuetara MS, Ponton J. Early diagnosis of invasive fungal infections caused by Aspergillus and other emerging mycelial fungi. Rev Iberoam Micol 2007; 24: 187-97.
108. Ramirez M, Castro C, Palomares JC et al. Molecular detection and identification of Aspergillus spp. from clinical samples using real-time PCR. Mycoses 2009; 52: 129-34.
109. Faber J, Moritz N, Henninger N, Zepp F, Knuf M. Rapid detection of common pathogenic Aspergillus species by a novel real-time PCR approach. Mycoses 2009; 52: 228-33.
110. Halliday C, Wu QX, James G, Sorrell T. Development of a nested qualitative real-time PCR assay to detect Aspergillus species DNA in clinical specimens. J Clin Microbiol 2005; 43: 5366-8.
111. Khan ZU, Ahmad S, Theyyathel AM. Diagnostic value of DNA and (1→3)- beta-D-glucan detection in serum and bronchoalveolar lavage of mice experimentally infected with Fusarium oxysporum. J Med Microbiol 2008; 57(Pt 1): 36-42.
112. Hrncirova K, Lengerova M, Kocmanova I et al. Rapid detection and identification of mucormycetes from culture and tissue samples by use of high-resolution melt analysis. J Clin Microbiol 2010; 48: 3392-4.
113. Ahmad S, Khan ZU, Theyyathel AM. Development of a nested PCR assay for the detection of Fusarium solani DNA and its evaluation in the diagnosis of invasive fusariosis using an experimental mouse model. Mycoses 2010; 53: 40-47.
114. Castelli MV, Buitrago MJ, Bernal-Martinez L, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol 2008; 46: 3412-6.
115. Frealle E, Decrucq K, Botterel F et al. Diagnosis of invasive aspergillosis using bronchoalveolar lavage in haematology patients: influence of bronchoalveolar lavage human DNA content on real-time PCR performance. Eur J Clin Microbiol Infect Dis 2009; 28: 223-32.
116. Logotheti M, Kotsovili-Tseleni A, Arsenis G, Legakis NI. Multiplex PCR for the discrimination of A. fumigatus, A. flavus, A. niger and A. terreus. J Microbiol Methods 2009; 76: 209-11.
117. Khan ZU, Ahmad S, Mokaddas E et al. Cerebral aspergillosis diagnosed by detection of Aspergillus flavus-specific DNA, galactomannan and (1→3)-beta-D-glucan in clinical specimens. J Med Microbiol 2007; 56(Pt 1): 129-32.
118. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 2003; 41: 5525-9.
119. Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998; 26: 1092-7.
120. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-5.
121. Baddley JW, Moser SA. Emerging fungal resistance. Clin Lab Med 2004; 24: 721-35, vii.
122. Balajee SA, Weaver M, Imhof A, Gribskov J, Marr KA. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004; 48: 1197-203.
123. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001; 45: 327-30.
124. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
125. Pujol I, Guarro J, Gene J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997; 39: 163-7.
126. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 9390: 1142-51.
127. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37: 3946-51.
128. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-2.
129. Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-403.
130. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-5.
131. Forrest G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis 2006; 19: 538-43.
132. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-47.
133. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-e65.
134. Cuenca-Estrella M, Ruiz-Diez B, Martinez-Suarez JV, Monzon A, Rodriguez-Tudela JL. Comparative in-vitro activity of voriconazole (UK-109, 496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999; 43: 149-51.
135. Walsh TJ, Peter J, McGough DA, Fothergill AW, Rinaldi MG, Pizzo PA. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 1995; 39: 1361-4.
136. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46: 62-68.
137. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: 106-17.
138. Cornely OA, Ullmann AJ, Karthaus M. Choosing a study population for the evaluation of antifungal prophylaxis. Clin Infect Dis 2005; 40: 1699, author reply 701.
139. Yanada M, Kiyoi H, Murata M et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 2006; 45: 259-64.
140. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2020.